Burning Rock Biotech Ltd
BNR- Exchange
- Nasdaq
- Industry
- Services-Medical Laboratories
- SEC CIK
- 0001792267
No open-market purchases or sales by Burning Rock Biotech Ltd insiders were filed in the last 90 days; 17 institutions reported holding it in 13F filings for Q2 2026, worth $14.7M in total; no superinvestor holds it.
13F holders, Q4 2021
Institutional positions in Burning Rock Biotech Ltd as of Dec 31, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 62
- −25 vs. Q3 2021
- Shares held
- 26.7M
- −801.3K (−2.9%) vs. Q3 2021
- Total value
- $243.0M
- −$247.8M (−50.5%) vs. Q3 2021
- New holders
- 14
- 16 more added
- Sold out
- 39
- 23 more reduced
Compare with Q3 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting BNR on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 17 | $14.7M |
| Q1 2026 | 16 | $27.4M |
| Q4 2025 | 16 | $34.9M |
| Q3 2025 | 16 | $12.4M |
| Q2 2025 | 17 | $4.57M |
| Q1 2025 | 18 | $9.65M |
| Q4 2024 | 21 | $15.8M |
| Q3 2024 | 18 | $6.69M |
| Q2 2024 | 18 | $13.2M |
| Q1 2024 | 20 | $15.1M |
| Q4 2023 | 19 | $18.7M |
| Q3 2023 | 28 | $20.1M |
| Q2 2023 | 32 | $46.2M |
| Q1 2023 | 34 | $60.8M |
| Q4 2022 | 42 | $49.6M |
| Q3 2022 | 52 | $55.5M |
| Q2 2022 | 50 | $71.2M |
| Q1 2022 | 46 | $274.5M |
| Q4 2021 | 62 | $243.0M |
| Q3 2021 | 87 | $490.9M |
| Q2 2021 | 86 | $793.4M |
| Q1 2021 | 54 | $634.7M |
Institutions, Q4 2021
Shares, value and share of portfolio for each institution holding Burning Rock Biotech Ltd; share changes are against Q3 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| DekaBank Deutsche Girozentrale | 0 | $0 | 0.00% | −2,650−100.0% | Sold out |